Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder

Psychiatry Research

Volumn 177, Issue 3, 2010, Pages 323-329

  Herrera Guzmán, Ixchel ^a,b,c   Herrera Abarca, Jorge E ^a,c   Gudayol Ferré, Esteve ^a,b,c   Herrera Guzmán, Daniel ^d   Gómez Carbajal, Lizbeth ^b   Peña Olvira, Miriam ^b   Villuendas González, Erwin ^b   Joan, Guàrdia Olmos ^e  

^a Clinica de Enfermedades Crónicas Y de Procedimientos Especiales C E C Y P E   (Mexico)

^b UNIVERSIDAD MICHOACANA DE SAN NICOLÁS DE HIDALGO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d El Centro Michoacano de Salud Mental Morelia   (Mexico)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Major depressive disorder; Neuropsychological assessment; Neuropsychology; Selective serotonin reuptake inhibitor; Serotonin noradrenaline reuptake inhibitor

Indexed keywords

DULOXETINE; ESCITALOPRAM;

ADULT; ARTICLE; ATTENTION; COGNITION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG RESPONSE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; WORKING MEMORY;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CITALOPRAM; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHOMETRICS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952674864     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.03.006     Document Type: Article

References (45)

1. Airaksinen E., Larsson M.L., Lundberg I., Forsell Y. Cognitive functions in depressive disorders: evidence from a population based study. Psychological Medicine 2004, 34:83-91.
2. Alexopoulos G.S., Meyers B.S., Young R.C., Kaylam B., Wakuma T., Gabrielle M., Sirey J.A. Executive Dysfunction and long-term outcome of geriatric depression. Archives of General Psychiatry 2000, 57:285-290.
3. Austin M.P., Mitchell P., Wilheim K., Parker G., Hickie I., Brodaty H., Chan J., Eyers K., Millie M., Hadzi-Pavlovic D. Melancholic depression: A distinct pattern of frontal impairment in melancholia. Psychological Medicine 1999, 24:73-85.
4. Austin M.P., Mitchell P.M., Goodwin G.M. Cognitive deficits in depression. British Journal of Psychiatry 2001, 178:200-206.
5. Battista-Cassano G., Puca F., Scapicchio P.L., Trabucchi M. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. Journal of Clinical Psychiatry 2002, 63:396-402. for the Italian Study Group on Depression in Elderly Patients.
6. Calabrese F., Molteni R., Maj P.F., Cattaneo A., Gennarelli M., Racagni G., Riva M.A. Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology 2007, 32:2351-2359.
7. Chamberlain R., Sahakian B. Cognition in mania and depression. Psychological models and clinical implications. Current Psychiatry Reports 2004, 6:451-458.
8. Chamberlain R., Muller U., Robbins T.W., Sahakian B. Neuropharmacological modulation of cognition. Current Opinion in Neurology 2006, 19:607-612.
9. Clark L., Sarna A., Goodwin G.M. Impairment of executive function but not memory in first-degree relatives of patients with bipolar I disorder and in euthymic patients with unipolar depression. American Journal of Psychiatry 2005, 162:1980-1982.
10. Collette F., Hogge M., Salmon E., Linden VanDer Exploration of the neural substrates of executive functioning by functional neuroimaging. Neuroscience 2006, 139:209-221.
11. Constant E.L., Adam S., Gillain B., Seron X., Bruyer R., Seghers A. Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depression and Anxiety 2005, 21:78-89.
12. Elliot R., Sahkian B.J., Herrod J.J., Robbins T.W., Paykel E.S. Neuropsychological impairments in unipolar depression. The influence of perceived failure on subsequent performance. Psychological Medicine 1996, 26:975-989.
13. Fergusson J.M., Wesnes K.A., Schwartz G.E. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. International Clininical Psychopharmacology 2003, 18:9-14.
14. Gualtieri T.C., Johnson L.G., Benedict K.B. Neurocognition in depression: patients on and off medication versus healthy comparison subjects. Journal of Neuropsychiatry and Clinical Neurosciences 2006, 18:217-225.
15. Hamilton M. Development of a rating scale for primary depressive illness 1967, British Journal of Social and Clinical Psychology.
16. Harvey P.O., LeBastard G., Pochon J.B., Levy R., Alliaire J.F., Dubois B., Fossati P. Executive functions and updating the contents of working memory in unipolar depression. Journal of Psychiatric Research 2004, 38:567-576.
17. Henry J.D., Crawford J.R. A Meta-analytic review of verbal fluency deficits in depression. Journal of clinical and Experimental Neuropsychology 2005, 27:78-101.
18. Herrera-Guzmán I., Gudayol-Ferré E., Herrera-Guzmán D., Guárdia-Olmos J., Hinojosa-Calvo E., Herrera-Abarca J.E. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. Journal of Psychiatric Research 2009, 43:855-863.
19. Jaeger J., Berns S., Uzelac S., Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Research 2006, 145:39-48.
20. Koetsier G.C., Volkers A.C., Tulen J.H.M., Passchier J., Van der Broek W., Bruijn J.A. CPT Performance in major depressive disorder before and after treatment with imipramine or fluvoxamine. Journal of Psychiatric Research 2002, 36:391-397.
21. Levkowitz Y., Catfori R., Avital A., Ritcher-Levin G. The SSRI drug fluoxetine but not the noradrenergic tricyclic drug desipramine, improves memory performance during acute major depression. Brain Research Bulletin 2002, 58:345-350.
22. Lezak M.D., Howiesson D.B., Loring D.W. Neuropsychological Assessment 2004, Oxford University Press, Oxford. Fourth Edition.
23. Michopoulos I., Zervas I.M., Papakosta V.M., Tsaltsas E., Papageorgiu C., Manéis T., Papakostas Y.G., Lykouras L., Soldatos C.R. Set Shifting deficits in melancholic vs. Nonmelancholic depresion: preliminary findings. European Psychiatry 2006, 21:361-363.
24. Millan M.J. The role of monoamines in the actions of established and novel antidepressant agents: a critical review. European Journal of Pharmacology 2004, 500:371-384.
25. Moron J.A., Brockington A., Wise R.A., Rocha B.A., Hope B.T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knockout mouse lines. Journal of Neuroscience 2002, 22:389-395.
26. Nebes R.D., Pollock B.G., Houck P.R., Butters M.A., Mulsant B.H., Zmunda M.D., Reynolds C.F. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double blind clinical trial with nortriptyline and paroxetine. Journal of Psychiatric Research 2003, 37:99-108.
27. Paelecke-Habermann I., Pohl J., Leplow B. Attention and executive functions in remitted major depression patients. Journal of Affect.ive Disorders 2005, 89:125-135.
28. Paradiso S., Lamberti G., Harvey M., Robinson R. Cognitive Impairment in the Euthymic Phase of Chronic Unipolar Depression. Journal of Nervous and Mental Disorders 1997, 185:748-754.
29. Porter R.J., Gallagher P., Thompson J.M., Youg A.H. Neurocognitive impairment in drug free patients with major depressive disorder. British Journal of Psychiatry 2003, 182:214-220.
30. Rantamäki T., Hendolin P., Kankaanpää A., Mijatovic J., Piepponen P., Domenici E., Chao M.V., Männistö P.T., Castrén E. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology 2007, 32:2152-2162.
31. Raskin J., Wiltse C.G., Siegal A., Sheikh J., Xu J., Dinkel J.J., Rotz B.T., Mohs R.C. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo controlled trial. American Journal of Psychiatry 2007, 164:900-909.
32. Ravnkilde B., Videbech P., Clemmensen K., Egander A., Rasmunsen N.A., Rosenberg N. Cognitive deficits in major depression. Scandinavian Journal of Psychology 2002, 43:239-251.
33. Robbins T.W., James M., Owen A.M., Sahakian B.J., MicIness L., Rabitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 1994, 5:266-281.
34. Rogers M., Bradshaw J.L., Pantellis C., Philip J.G. Frontostriatal deficits in unipolar major depression. Brain Research Bulletin 1998, 472:97-310.
35. Rogers M.A., Kasai K., Matsuo K., Fukuda R., Iwanami A., Nakagome K., Fukuda M., Nobumasa Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neuroscience Research 2004, 50:1-11.
36. Saarelainen T., Hendollin P., Lucas G., Koponen E., Sairanen M., McDonald E., Agerman K., Haapasalo A., Nawa H., Aloyz R., Ernfors T., Castren E. Activation of TrKb neurotrophin receptor i.e. induced by antidepressant drugs and is required for antidepressant induced behavioral effects. Journal of Neuroscience 2003, 23:1089-1094.
37. Sairanen M.O., O' Leary J.E., Knuuttila J.E., Castren E. Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medialprefrontal cortex in the rat. Neuroscience 2007, 144:368-374.
38. Sheehan D.V., Lecrubier Y., Sheehan K.H. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl 20):22-33.
39. Sobin C., Sackeim H. Psychomotor symptoms of depression. American Journal of Psychiatry 1997, 154:4-17.
40. Stahl S.M., Zhang L., Damatarca C., Grady M. Brain circuits determine destiny in depression: a novel approach to psychopharmacology of wakefulness, fatigue, and executive dysfunction in Major Depressive Disorder. Journal of Clinical Psychiatry 2003, 64(suppl. 11):6-17.
41. Stuss D.T., Benson D.F. The Frontal Lobes 1986, Raven Press, New York.
42. Tratado de psiquiatría 2005, vol. II. Ars Médica, Barcelona. J. Vallejo-Ruibola, C. Leal-Cercòs (Eds.).
43. Weiland-Fielder P., Erickson K., Waldeck T., Luckenbaurg D.A., Pike D., Boone O., Charney D., Neumeister A. Evidence for continuing neuropsychological impairments in depression. Journal of Affective Disorders 2004, 82:253-258.
44. Wroolie T.E., Williams K.E., Keller J., Zappert L.N., Shelton S.D., Kenna M.A., Reynolds M.F., Rasgon N.L. Mood and neuropsychological changes in women with midlife depression treated with escitalopram. Journal of Clinical Psychopharmacology 2006, 26:361-366.
45. Zobel A.W., Schulze-Rauschenbach S., Von Widdern O., Metten M., Freyman N., Grasmäder K., Pfeiller U., Schnell S., Wagner M., Maier W. Improvement of working memory but not declarative memory is correlated with HPA normalization during antidepressant treatment. Journal of Psychiatric Research 2004, 38:377-383.